Literature DB >> 29559174

Mucoepidermoid carcinoma of the parotid gland: A National Cancer Database study.

Karthik Rajasekaran1, Vanessa Stubbs2, Jinbo Chen3, Pratyusha Yalamanchi2, Steven Cannady2, Jason Brant2, Jason Newman2.   

Abstract

OBJECTIVE: To describe the demographics, tumor characteristics, and prognostic features of mucoepidermoid carcinoma of the parotid gland.
MATERIALS AND METHODS: A retrospective study of the National Cancer Database was reviewed for all mucoepidermoid carcinomas of the parotid gland between 2004 and 2012). Patient demographics and tumor characteristics were abstracted and analyzed. Univariate and multivariate Cox multivariate regression models were used to identify predictors of survival.
RESULTS: A total of 4431 patients met inclusion criteria. Average age at diagnosis was 57 years (median 62, SD 19), with no overall sex preference (52% female), and majority white (78%). The 1-year overall survival was 92.9% (95% CI [92.1-93.6]) and 5-year overall survival was 75.2% (95% CI [73.8-76.7%]). Median overall survival was not reached at 5 years. Factors associated with decreased survival were increasing age, comorbidities, high tumor grade, advanced pathologic group stage, and positive surgical margins. Female sex was the only factor associated with improved survival. Controlling for either histopathologic grade or pathologic stage to determine how patient demographics and tumor characteristics affected overall survival yielded similar results. Of note, intermediate grade tumors, although not independently associated with worse survival, when seen in conjunction with tumors ≥T2 and/or ≥N2, a negative impact on overall survival was seen.
CONCLUSION: Although mucoepidermoid carcinoma of the parotid gland is the most common parotid gland malignancy, it is still a rare tumor with a lack of large population-based studies. Advanced stage and high-grade tumors are significant predictors of decreased survival. Females have improved survival compared to males.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Demographics; Mucoepidermoid carcinoma; National Cancer Database; Parotid gland; Prognostic factors; Survival; Tumor characteristics

Mesh:

Year:  2018        PMID: 29559174     DOI: 10.1016/j.amjoto.2018.03.022

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  12 in total

1.  Role of elective neck dissection and adjuvant radiation therapy in patients with polymorphous adenocarcinoma.

Authors:  Alyssa M Civantos; Shreya Viswanathan; Aman Prasad; Solymar Torres Maldonado; Robert M Brody; Steven B Cannady; Jason G Newman; Rabie M Shanti; Jason A Brant; Karthik Rajasekaran
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-03       Impact factor: 2.503

2.  Overall and cause-specific survival for mucoepidermoid carcinoma of the major salivary glands: Analysis of 2210 patients.

Authors:  Zachary C Taylor; Erin A Kaya; Jeffrey D Bunn; Zachary D Guss; Brian J Mitchell; Robert K Fairbanks; Wayne T Lamoreaux; Aaron E Wagner; Ben J Peressini; Christopher M Lee
Journal:  World J Clin Oncol       Date:  2020-12-24

3.  Morphologic CT and MRI features of primary parotid squamous cell carcinoma and its predictive factors for differential diagnosis with mucoepidermoid carcinoma.

Authors:  Xiaohua Ban; Huijun Hu; Yue Li; Lingjie Yang; Yu Wang; Rong Zhang; Chuanmiao Xie; Cuiping Zhou; Xiaohui Duan
Journal:  Insights Imaging       Date:  2022-07-15

4.  Mucoepidermoid carcinoma of the head and neck: CRTC1/3 MAML 2 translocation and its prognosticators.

Authors:  Stijn van Weert; Birgit I Lissenberg-Witte; Elisabeth Bloemena; C René Leemans
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-08-17       Impact factor: 3.236

5.  Management and outcome of parotid mucoepidermoid carcinoma by histological grade: A 21-year review.

Authors:  Masataka Taniuchi; Ryo Kawata; Tetsuya Terada; Masaaki Higashino; Hiromi Nishimura; Yoshitaka Kurisu; Hiroko Kuwabara; Yoshinobu Hirose
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-05-21

6.  Nomogram to predict the prognosis of parotid gland mucoepidermoid carcinoma: a population-based study of 1306 cases.

Authors:  Jian Sun; Yang Sun; Fei Yang; Qianrong Zhou; Wenjuan Liu; Yong Cheng; Xingwen Wu; Tinglan Chen; Ruixue Li; Borui Huang; Wael Att; Youcheng Yu; Wei Bi
Journal:  PeerJ       Date:  2019-07-01       Impact factor: 2.984

7.  Metastatic mucoepidermoid carcinoma to the pleura: a case report.

Authors:  Simran Mashiana; Ernesto Martinez Duarte
Journal:  J Med Case Rep       Date:  2022-02-16

8.  A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.

Authors:  Hye Ryeon Kim; Su Jin Lee; Sehhoon Park; Hyun Ae Jung; Se-Hoon Lee; Han-Sin Jeong; Man Ki Chung; Myung-Ju Ahn
Journal:  Cancer Res Treat       Date:  2021-11-01       Impact factor: 5.036

9.  Role of intraparotid node metastasis in mucoepidermoid carcinoma of the parotid gland.

Authors:  Xingyu Niu; Qigen Fang; Fei Liu
Journal:  BMC Cancer       Date:  2019-05-03       Impact factor: 4.430

Review 10.  Role of Hydrogen Sulfide in Oral Disease.

Authors:  Dong-Dong Wu; Ebenezeri Erasto Ngowi; Yuan-Kun Zhai; Yi-Zhen Wang; Nazeer Hussain Khan; Ahmad Fadhil Kombo; Saadullah Khattak; Tao Li; Xin-Ying Ji
Journal:  Oxid Med Cell Longev       Date:  2022-01-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.